Skip to main content
Download PDF

Very high HDL-C (high-density lipoprotein cholesterol) is associated with increased cardiovascular risk in patients with NSTEMI (non-ST-segment elevation myocardial infarction) undergoing PCI (percutaneous coronary intervention)

BMC Cardiovascular Disorders volume 23, Article number: 357 (2023) Cite this article

Abstract

Background

Studies in populations with or without cardiovascular disease have shown that very high HDL-C levels are associated with an increased risk of cardiovascular events. However, the exact relationship between HDL-C levels and long-term prognosis remains unknown in patients with myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI).

Methods

This was a post hoc secondary analysis of long-term follow-up results in patients undergoing PCI open-label, observational cohort study. Patients with MI who had undergone PCI were enrolled. Restricted cubic spline (RCS) analysis and logistic regression analysis were performed to assess the relationship between HDL-C levels and the risk of cardiovascular events.

Results

A total of 1934 patients with MI undergoing PCI were enrolled in our analysis and our population was divided in 3 groups according to the HDL-C plasma levels: HDL-C < 40 mg/dL (low HDL-C); HDL-C between 40 and 80 mg/ dL (medium HDL-C); and HDL-C > 80 mg/dL (high HDL-C). RCS analysis showed a nonlinear U-shaped association between HDL-C levels and major adverse cardiac and cerebrovascular events (MACCE) in patients with NSTEMI with adjusted variables. After adjusting for potential confounders, the follow-up analysis indicated that high risk group had elevated occurrence of MACCE than low risk group (HDL-C 35 and 55 mg/dL) (OR:1.645, P = 0.006).

Conclusions

Our analysis demonstrated that there is a U-shaped association between HDL-C and MACCE in patients with NSTEMI undergoing PCI.

Peer Review reports

Introduction

High-density lipoprotein cholesterol (HDL-C) has been considered for many years to be an atherosclerotic and cardioprotective property, a postulate mainly based on seminal epidemiological studies indicating that each 1 mg/dL increase in HDL-C is accompanied by a ≈ 2–3% reduction in the risk of cardiovascular death [1,2,3,4,5,6,7]. However, recent clinical trials and genetic studies investigating the rise of HDL-C through pharmacological therapy or genetic polymorphisms, respectively, have failed to show an effect on major adverse cardiac and cerebrovascular events (MACCE) [8,9,10,11]. These findings challenge the therapeutic value of pharmacological HDL-C elevating treatment and contribute to in-depth studies of prognostic value of HDL-C [12,13,14]. More recently, studies in populations free of cardiovascular disease have shown that very high HDL-C levels are associated with an increased mortality risk, and the same conclusion has been confirmed in population with coronary artery disease or hypertension [7, 15,16,17,18]. Nevertheless, the exact relationship between HDL-C levels and specific cardiovascular events remains unknown, especially in a high-risk population like patients with myocardial infarction (MI) undergoing percutaneous coronary intervention (PCI).

To further clarify this issue, we have analyzed the relationship between HDL-C levels and long-term prognosis in patients MI undergoing PCI in a high-volume PCI centre, with a long-term follow-up.

Methods

Study population

This was a post hoc secondary analysis of an open-label, observational cohort study in which we enrolled patients undergoing PCI [18, 19]. The study was conducted in consecutive patients enrolled at a single high-volume PCI center between July 2009 and August 2011. Qualitative and quantitative coronary angiographic analyses were performed according to standard methods. PCI was performed using standard techniques. All patients received loading doses of aspirin (300 mg) and clopidogrel (300 mg) before coronary intervention unless they were already receiving antiplatelet therapy. The treatment strategy, stenting techniques, selection of stent type, and use of glycoprotein IIb/IIIa receptor inhibitors or intravascular ultrasound were all left to the surgeon’s discretion. All patients were prescribed 100 mg/day aspirin indefinitely and clopidogrel 75 mg/day for at least the first 12 months after the procedure [18]. In brief, we included men and women over 18 years old who underwent PCI and had HDL-C levels measured during hospitalization. For our analysis, patients undergoing PCI were selected on the basis of the following inclusion criteria: age ≥ 18 years; confirmed diagnosis of MI; at least one follow-up visit. We excluded patients without record of HDL-C level. The trial was conducted according to the Declaration of Helsinki and was approved by the ethics committee of the First Affiliated Hospital of Zhengzhou University.

Cardiovascular risk factor and end points

Information on demographics and relevant risk factors was obtained at enrollment, including age, sex, stroke history, old myocardial infarction (OMI), heart failure, atrial fibrillation, peripheral vascular disease, hypertension, diabetes, and smoking habit. Auxiliary examination information was obtained during hospitalization including HDL-C, low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG), glucose, uric acid (UA) and serum creatinine (Scr).

Primary end points were defined as major adverse cardiac and cerebrovascular events (MACCE), namely death, MI and stroke. Clinical follow-up was conducted through patient visits, telephone interviews, and review of medical records. Independent investigators entered the data, and an independent committee adjudicated clinical events. Between July 2009 and August 2011, 2 735 patients were treated by PCI [18]. 2533 patients (92.6%) were followed up for a median of 29.8 months (interquartile 25.6–34 months).

Statistical analysis

Data are presented as mean (SD) for continuous variables and in percentage form for categorical variables. ANOVA and χ2 distribution were used for exploratory statistics. Our study population was divided into three groups based on HDL-C levels (mg/dL < 40, 40–80, and > 80) to examine the association between HDL-C levels and the incidence of cardiovascular events. Restricted cubic spline analysis was performed to assess the relationship between HDL-C levels and the risk of cardiovascular events. A logistic regression analysis was applied to assess the effects of HDL-C on cardiovascular events during follow-up after adjusting for age, sex, hypertension, diabetes, baseline BP values, baseline heart rate, smoking habit, LDL, TG, TC, UA and Scr. A 2-tailed P < 0.05 was considered statistically significant. Statistical analysis was performed using IBM SPSS 25 (IBM Corporation, Armonk, NY) and R Statistical Software (version 4.1.0; R Foundation for Statistical Computing).

Results

A total of 2 533 patients were enrolled at the high-volume PCI centre; of these, 1934 patients (1305 men [67.5%]; 629 women [32.5%]) were included in our analysis (Fig. 1). Patients with ST-elevation myocardial infarction (STEMI) accounted for 29.3% of cases and patients with non-ST elevation ACS(NSTE-ACS) accounted for 70.7% of cases. Our population was divided in 3 groups (Table 1) according to the HDL-C plasma levels: specifically, the first group includes 1011 patients with HDL-C below 40 mg/dL (low HDL-C); the second group includes 905 patients with HDL-C plasma levels between 40 and ≤ 80 mg/dL (medium HDL-C); and 18 patients with HDL- C > 80 mg/dL constituted the third group (high HDL-C). The main demographic and clinical characteristics of these 3 groups are displayed in Table 1. Importantly, no significant difference among our groups was found in terms of medications (Table 2).

Fig. 1
figure 1

Flow chart of the study. Abbreviations: PCI, Percutaneous coronary intervention; HDL-C, High-density lipoprotein cholesterol; MI, Myocardial infarction

Full size image
Table 1 Baseline characteristics of different levels of HDL-C.
Full size table
Table 2 Distribution of Medications in Our Population
Full size table

We then plotted the spline curves of the Logistics regression models to estimate the relative hazard ratio in our population, no remarkable nonlinear U-shaped association between HDL-C levels and MACCE was not observed in patients with MI(Fig. 2). Intriguingly, when subdividing our population in patients with STEMI and patients with NSTEMI, we found a nonlinear U-shaped association between HDL-C levels and MACCE in patients with NSTEMI (P = 0.026) (Fig. 3A and B).

Fig. 2
figure 2

Spline curves of the Logistics regression models for HDL-C and the risk of cardiovascular events in patients with MI undergoing PCI. Spline plot showing the association between HDL-C and risk of cardiovascular events in patients with MI undergoing PCI. The shaded area represents the 95% CI. Abbreviations: PCI, Percutaneous coronary intervention; HDL-C, High-density lipoprotein cholesterol; MI, myocardial infraction; MACCE, Major adverse cardiac and cerebrovascular events; RCS, Restricted cubic spline; CI, Confidence interval; OR, Odds ratio

Full size image
Fig. 3
figure 3

Spline curves of the Logistics regression models for HDL-C and the risk of cardiovascular events in patients with STEMI and patients with NSTEMI undergoing PCI. Spline plots showing the association between HDL-C and risk of cardiovascular events in patients with STEMI (A) and patients with NSTEMI (B) undergoing PCI. The shaded area represents the 95% CI. Abbreviations: PCI, Percutaneous coronary intervention; HDL-C, High-density lipoprotein cholesterol; MI, Myocardial infraction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, Non-ST-segment elevation myocardial infarction; MACCE, Major adverse cardiac and cerebrovascular events; RCS, Restricted cubic spline; CI, Confidence interval; OR, Odds ratio

Full size image

Patients were divided into high-risk group (< 35 and > 55 mg/dl) and low-risk group (35–55 mg/dl) according to their HDL-C levels in patients with NSTEMI. As shown in Table 3, the incidences of death and MACCE were higher in the high-risk group. During the mean follow-up of 29 months, a total of 83 patients in high-risk group (n = 580) and 76 patients in low-risk group (n = 787) occurred MACCE. The incidence of MACCE in high-risk group were higher than that in the low-risk group (14.30% vs. 9.7%, P = 0.005). We then compared baseline difference in patients with NSTEMI (Additional File Table 1). As shown in Fig. 4, after having adjusted for potential confounders, the follow-up analysis indicates that high-risk group had elevated occurrence of MACCE than low-risk group in patients with NSTEMI (OR:1.645, P = 0.006).

Table 3 Clinical events according to the levels of HDL-C in patients with NSTEMI
Full size table
Fig. 4
figure 4

The follow-up analysis of MACCE. Patients were divided into high-risk group(< 35 and > 55 mg/dl) and low-risk group (35–55 mg/dl) according to their HDL-C levels. After having adjusted for potential confounders, the follow-up analysis indicated that high-risk group had elevated occurrence of MACCE than low-risk group in patients with NSTEMI (B) undergoing PCI (HR:1.723, P = 0.002). Abbreviations: OMI, Old myocardial infraction; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; LDL-C, Low-density lipoprotein cholesterol; HDL-C group, High-density lipoprotein cholesterol group; NSTEMI, Non-ST-segment elevation myocardial infarction; OR, Odds ratio; CI, Confidence interval

Full size image

Discussion

Our results demonstrate that the association between HDL-C and risk of major adverse cardiac and cerebrovascular events (MACCE) is U-shaped in patients with NSTEMI undergoing PCI, with both low and high concentration groups appearing elevated occurrence of MACCE compared with the HDL-C 35 and 55 mg/dL group.

The mechanism of HDL protection for the heart mainly includes the reverse transport of cholesterol and its antioxidant capacity [20,21,22,23,24,25,26]. However, clinical trials and genetic studies investigating the rise of HDL-C using pharmacological therapy and genetic polymorphisms, respectively, have failed to show an effect on major adverse cardiac and cerebrovascular events (MACCE) [8,9,10,11]. Studies in population without cardiovascular disease have shown that extremely high HDL-C levels are associated with an increased risk of death and same results were found in people with coronary artery disease [15,16,17]. And very high Lp(a) levels (above the threshold of 60 mg/ dL) was associated with a higher recurrence of cardiovascular events In our study, the correlation of very high HDL and major adverse cardiac and cerebrovascular events (MACCE)were also observed in patients with NSTEMI undergoing PCI. The increased cardiovascular risk associated with elevated levels of HDL-C was not confirmed in patients with STEMI undergoing PCI. Erosion predominantly provokes NSTEMI while plaque rupture associates more commonly with STEMI. Lipid lowering, particularly statin therapy, lessens the lipid core, and augments the relative amount of fibrous tissue in atherosclerotic plaques [27] and 95% of our population undergone statin therapy. Another reason is the low proportion of events may result in less precise estimates compared with the overall cohort.

After having adjusted for potential confounders, we found high HDL-C concentration groups appear elevated occurrence of MACCE compared with the medium group in patients with NSTEMI undergoing PCI, which contradicts the protective effect of high HDL-C on the heart. Our observational study does not clarify whether the association between high HDL-C levels and increased cardiovascular risk is causal. Thus, we can only speculate on the possible pathogenetic mechanisms. A high HDL cholesterol reading cannot represent an efficient transport system moving large amounts of cholesterol to the liver for excretion, such as a problem with disembarkation at the liver. In fact, since cholesterol exchange between HDL particles and peripheral cells is bidirectional, it is possible that HDL could become a cholesterol donor to peripheral cells in the oversaturated state. Lipid trapped within HDL particles contribute to increased cardiovascular risk[28].

Immediate revascularization is the most effective intervention to reduce mortality after MI. Paradoxically, reperfusion of ischaemic tissue promotes further myocardial damage mediated by mitochondrial reactivation, rapid recovery of physiological pH, and excess ROS production. HDL has been suggested as a possible treatment strategy for patients with acute comorbid syndromes due to its antioxidant and pro-survival properties. Animal studies have confirmed that HDL isolated from healthy subjects protects the myocardium from ischemia/reperfusion injury. In contrast, HDL derived from patients in the acute phase of MI lost its ability to protect the heart from experimental MI [29]. These results may be related to serum amyloid A (SSA), whose level are positively correlated with cardiovascular disease [30,31,32]. SAA upregulation triggers its association with HDL, replacing ApoA-I as the main apolipoprotein of HDL [33, 34]. Binding of SAA to HDL helps to convert functional anti-atherosclerotic HDL to dysfunctional pro-atherosclerotic HDL. HDL particles containing SAA have a reduced ability to transport cholesterol in the reverse direction from macrophages. This correlates with the ability of SAA to interact with cell-surface proteoglycans, which prevents HDL from adequately interacting with the plasma membrane to promote cholesterol efflux [35, 36]. Another underlying mechanism is that there is an inverse U-shaped relationship between triglyceride-rich lipoprotein (TGRL) and HDL-C concentration. The ability of HDL to acquire cholesterol during lipolysis is reduced after the knockout of TGRL. Therefore, the transfer of free cholesterol to HDL via TGRL lipolysis may be the basis of the U-shaped relationship between HDL-C and cardiovascular diseases [37].

However, there are still several limitations in our study that can be improved in the future. Firstly, our observational study was from a single-center, therefore, our finding may not exactly apply to other population. The second limitation was the small number of patients with very high HDL-C; nevertheless, it did not undermine the demonstration of a significant increase in the cardiovascular risk after adjustment for confounders. The third limitation is that post-PCI management, such as lipid-lowering therapy, varied considerably compared to current clinical standards since the study period was over ten years ago. The fourth limitation is that we applied logistic regression analysis instead of COX proportional hazards model due to the lack of data about the time-event relationship. The fifth limitation is that the baseline information did not contain lipoprotein(a), which has been verified as an influencing factor of cardiovascular events in patients with AMI undergoing PCI [38, 39].

Conclusion

Our data indicate that there is a U-shaped association between HDL-C and MACCE in patients with NSTEMI undergoing PCI during a long-term follow-up. Low and high concentration groups showed elevated risk of MACCE compared with the HDL-C 35 and 55 mg/dL group. Our finding may help physicians manage dyslipidemia in patients with NSTEMI undergoing PCI.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

HDL:

High-density lipoprotein

HDL-C:

High-density lipoprotein cholesterol

PCI:

Percutaneous coronary intervention

CHD:

Coronary heart disease

MI:

Myocardial infarction

STEMI:

ST-segment elevation myocardial infarction

NSTEMI:

Non-ST-segment elevation myocardial infarction

PCI:

Percutaneous coronary intervention

MACCE:

Major adverse cardiac and cerebrovascular events

TVR:

Target vessel revascularization

OMI:

Old myocardial infarction

SBP:

Systolic blood pressure

DBP:

Diastolic blood pressure

LDL-C:

Low-density lipoprotein cholesterol

TC:

Total cholesterol

TG:

Triglycerides

UA:

Uric acid

Scr:

Serum creatinine

ACEI:

Angiotensin-converting enzyme inhibitor

ARNI:

Angiotensin receptor neprilysin inhibitor

CETP:

Cholesteryl ester transfer protein

AF:

Atrial fibrillation

TGRL:

Triglyceride-rich lipoprotein

SSA:

Serum amyloid A

RCS:

Restricted cubic spline

OR:

Odds ratio

CI:

Confidence interval

References

  1. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study Arteriosclerosis. 1988;8(6):737–41.

    CAS  PubMed  Google Scholar 

  2. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322(24):1700–7.

    Article  CAS  PubMed  Google Scholar 

  3. Sourlas A, Kosmas CE. Inheritance of high and low HDL: mechanisms and management. Curr Opin Lipidol. 2019;30(4):307–13.

    Article  CAS  PubMed  Google Scholar 

  4. Casula M, Colpani O, Xie S, Catapano AL, Baragetti A. HDL in Atherosclerotic Cardiovascular Disease: in search of a role. Cells. 2021;10(8):1869. Published 2021 Jul 23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective american studies. Circulation. 1989;79(1):8–15.

    Article  CAS  PubMed  Google Scholar 

  6. Rader DJ, Hovingh GK. HDL and cardiovascular disease. Lancet. 2014;384(9943):618–25.

    Article  CAS  PubMed  Google Scholar 

  7. Trimarco V, Izzo R, Morisco C, et al. High HDL (high-Density lipoprotein) cholesterol increases Cardiovascular Risk in Hypertensive Patients. Hypertension. 2022;79(10):2355–63.

    Article  CAS  PubMed  Google Scholar 

  8. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22.

    Article  CAS  PubMed  Google Scholar 

  9. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study [published correction appears in Lancet. 2012 Aug 11;380(9841):564]. Lancet. 2012;380(9841):572–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–99.

    Article  CAS  PubMed  Google Scholar 

  11. Soppert J, Lehrke M, Marx N, Jankowski J, Noels H. Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Adv Drug Deliv Rev. 2020;159:4–33.

    Article  CAS  PubMed  Google Scholar 

  12. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12.

    Article  Google Scholar 

  13. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med. 2017;376(20):1933–42.

    Article  PubMed  Google Scholar 

  14. Investigators AIM-HIGH, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy [published correction appears in N Engl J Med. 2012 Jul 12;367(2):189]. N Engl J Med. 2011;365(24):2255–67.

    Google Scholar 

  15. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017;38(32):2478–86.

    Article  CAS  PubMed  Google Scholar 

  16. Angeloni E, Paneni F, Landmesser U, et al. Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J. 2013;34(46):3557–62.

    Article  CAS  PubMed  Google Scholar 

  17. Fernández-Ruiz I. Very high HDL-C levels are associated with higher mortality in patients with CAD. Nat Rev Cardiol. 2022;19(8):504.

    Article  PubMed  Google Scholar 

  18. Yao HM, Wan YD, Zhang XJ, et al. Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre. BMJ Open. 2014;4(8):e004892.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yao H-M et al. (2014), Data from: long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI center, Dryad, Dataset, https://doi.org/10.5061/dryad.13d31.

  20. Yamauchi Y, Hayashi M, Abe-Dohmae S, Yokoyama S. Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J Biol Chem. 2003;278(48):47890–7.

    Article  CAS  PubMed  Google Scholar 

  21. Brewer HB Jr, Remaley AT, Neufeld EB, Basso F, Joyce C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004;24(10):1755–60.

    Article  CAS  PubMed  Google Scholar 

  22. Jones MK, Catte A, Li L, Segrest JP. Dynamics of activation of lecithin: cholesterol acyltransferase by apolipoprotein A-I. Biochemistry. 2009;48(47):11196–210.

    Article  CAS  PubMed  Google Scholar 

  23. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol. 2010;21(4):312–8.

    Article  CAS  PubMed  Google Scholar 

  24. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res. 2006;47(11):2492–502.

    Article  CAS  PubMed  Google Scholar 

  25. Mishra VK, Palgunachari MN, McPherson DT, Anantharamaiah GM. Lipid complex of apolipoprotein A-I mimetic peptide 4F is a novel platform for paraoxonase-1 binding and enhancing its activity and stability. Biochem Biophys Res Commun. 2013;430(3):975–80.

    Article  CAS  PubMed  Google Scholar 

  26. Ostos MA, Conconi M, Vergnes L, et al. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21(6):1023–8.

    Article  CAS  PubMed  Google Scholar 

  27. Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing the Mechanisms of Acute Coronary Syndromes. Circ Res. 2019;124(1):150–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Xiang AS, Kingwell BA. Rethinking good cholesterol: a clinicians’ guide to understanding HDL. Lancet Diabetes Endocrinol. 2019;7(7):575–82.

    Article  PubMed  Google Scholar 

  29. Soares AAS, Carvalho LSF, Bonilha I, et al. Adverse interaction between HDL and the mass of myocardial infarction. Atherosclerosis. 2019;281:9–16.

    Article  CAS  PubMed  Google Scholar 

  30. Kosuge M, Ebina T, Ishikawa T, et al. Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ J. 2007;71(2):186–90.

    Article  CAS  PubMed  Google Scholar 

  31. Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep. 2009;14(5):187–96.

    Article  CAS  PubMed  Google Scholar 

  32. Zewinger S, Drechsler C, Kleber ME, et al. Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur Heart J. 2015;36(43):3007–16.

    CAS  PubMed  Google Scholar 

  33. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem. 1986;261(21):9644–51.

    Article  CAS  PubMed  Google Scholar 

  34. Wang DX, Liu H, Yan LR, et al. The relationship between serum amyloid A and apolipoprotein A-I in high-density lipoprotein isolated from patients with coronary heart disease. Chin Med J (Engl). 2013;126(19):3656–61.

    CAS  PubMed  Google Scholar 

  35. Artl A, Marsche G, Lestavel S, Sattler W, Malle E. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol. 2000;20(3):763–72.

    Article  CAS  PubMed  Google Scholar 

  36. Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res. 1995;36(5):1058–65.

    Article  CAS  PubMed  Google Scholar 

  37. Feng M, Darabi M, Tubeuf E et al. Free cholesterol transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis underlies the U-shape relationship between HDL-cholesterol and cardiovascular disease. Eur J Prev Cardiol.

  38. Gragnano F, Fimiani F, Di Maio M, et al. Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. Intern Emerg Med. 2019;14(4):621–5.

    Article  PubMed  Google Scholar 

  39. Cesaro A, Schiavo A, Moscarella E, et al. Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. J Cardiovasc Med (Hagerstown). 2021;22(3):151–61.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all contributing investigators of the Dryad database.

Funding

Funding for the study was provided by the National Nature Science Foundation of China [No. 81770231 and No. 81270203]; The Natural Science Foundation of Jiangsu [No. BK20161436]; Jiangsu Province Key Medical Research Project [No. K2019006]; Jiangsu Provincial Key Medical Discipline [No. ZDXKA2016023]; Jiangsu Provincial Key Research and Development Program [No. BE2016785].

Author information

Authors and Affiliations

  1. Department of Cardiology, Zhongda Hospital, Southeast University, 210009, Nanjing, China

    Lijuan Chen, Yuanyuan Zhao, Zheng Wang, Yifei Wang, Xiangwei Bo, Xiaoxi Jiang, Chunshu Hao, Chengwei Ju, Yangyang Qu & Hongjian Dong

  2. Department of Cardiology, Nanjing Lishui People’s Hospital, Zhongda Hospital Lishui Branch, 211200, Nanjing, China

    Lijuan Chen, Xiaoxi Jiang & Chengwei Ju

  3. School of Medicine, Southeast University, 210009, Nanjing, China

    Yuanyuan Zhao, Zheng Wang, Yifei Wang, Xiangwei Bo, Chunshu Hao, Yangyang Qu & Hongjian Dong

Authors
  1. Lijuan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuanyuan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zheng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yifei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiangwei Bo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaoxi Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chunshu Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chengwei Ju
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yangyang Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hongjian Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HD and LC had full access to all data. HD and ZW curated the data, performed the data and produced an initial draft of the manuscript. LC, YZ participated in critically revising the manuscript. All authors participated in concept and design of the present study.

Corresponding author

Correspondence to Hongjian Dong.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

Ethics committee of The First Affiliated Hospital of Zhengzhou University waived the need for informed consent due to retrospective study nature. And the study was conducted in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, L., Zhao, Y., Wang, Z. et al. Very high HDL-C (high-density lipoprotein cholesterol) is associated with increased cardiovascular risk in patients with NSTEMI (non-ST-segment elevation myocardial infarction) undergoing PCI (percutaneous coronary intervention). BMC Cardiovasc Disord 23, 357 (2023). https://doi.org/10.1186/s12872-023-03383-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12872-023-03383-9

Keywords

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us